Skip to main content

1 Result(s)

within Katharina Rohlf Remove this filter Cancer Research Remove this filter Immunology Remove this filter Oncology Remove this filter

and

  1. Article

    Open Access

    Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth

    Intrinsic or acquired resistance to HER2-targeted therapy is often a problem when small molecule tyrosine kinase inhibitors or antibodies are used to treat patients with HER2 positive breast cancer. Therefore,...

    Magdalena Keller, Katharina Rohlf… in Journal of Experimental & Clinical Cancer … (2023)

    Download PDF (4433 KB) View Article